Journal article
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Abstract
BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1.
METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a …
Authors
Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KAA; Lipka LJ; Liu X; Nicolau JC
Journal
New England Journal of Medicine, Vol. 366, No. 15, pp. 1404–1413
Publisher
Massachusetts Medical Society
Publication Date
April 12, 2012
DOI
10.1056/nejmoa1200933
ISSN
0028-4793